FDA Brief

Warning letters Drugs

FDA warning letter to

Glow Medispa, LLC dba Mint Med

LowIssued Jun 8Posted Jun 16Center for Drug Evaluation and Research (CDER)

FDA warns telehealth seller Mint Med that its website labels falsely suggest it compounds the semaglutide and tirzepatide drugs it sells.

What happened

FDA reviewed Mint Med's website, https://mintmed.com, in May 2026 and found it offers compounded semaglutide and tirzepatide drug products. The labels pictured on the site show "Mint Med" on the product label, which suggests Mint Med is the compounder of those drugs when it is not. FDA calls those representations false or misleading, which makes the products misbranded.

What FDA found

  1. The website shows compounded semaglutide and tirzepatide products with "Mint Med" on the label, which falsely suggests Mint Med made the drugs.

    FD&C Act § 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)
  2. Advertising or promoting a compounded drug with false or misleading claims misbrands the drug.

    FD&C Act § 502(bb) [21 U.S.C. § 352(bb)]
  3. Selling these misbranded drugs across state lines is a prohibited act.

    FD&C Act § 301(a) [21 U.S.C. § 331(a)]
  4. Compounded drugs must meet the conditions of section 503A or 503B to be exempt from the new drug approval requirements.

    FD&C Act §§ 503A and 503B [21 U.S.C. §§ 353a and 353b]

What FDA wants

FDA asks the company to send a written response to its Office of Compounding Quality and Compliance within 15 business days, naming the entities that make the drugs, providing sample labeling, and correcting or removing the misleading website claims.

Who should pay attention

  • telehealth platforms selling compounded semaglutide and tirzepatide
  • compounding pharmacies whose products are resold under another company's name
  • marketers that put their own name on drug labels they do not manufacture

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low